Vaxart, Inc. Files Form 8-K: Key Corporate Details for Investors

Vaxart, Inc. (OTCQX: VXRT) filed a Form 8-K with the U.S. Securities and Exchange Commission (SEC) dated April 20, 2026. The filing provides essential information for shareholders and potential investors regarding the company’s legal, regulatory, and operational status.

Key Points from the Report

• Filing Type and Date: Vaxart filed a Form 8-K, the SEC’s “Current Report,” used to announce major events that shareholders should know. The report is dated April 20, 2026.
• Company Details:
  • Registrant Name: Vaxart, Inc.
  • State of Incorporation: Delaware (DE)
  • File Number: 001-35285
  • Tax Identification Number: 59-1212264
  • Address: 170 Harbor Way, Suite 300, South San Francisco, CA 94080
  • Phone: (650) 550-3500
• Stock Information:
  • Title of Security: Common Stock, \$0.0001 par value
  • Trading Symbol: VXRT
  • Market: OTCQX® Best Market
• Emerging Growth Company Status: Vaxart is not classified as an emerging growth company under SEC definitions.
• Event or Other Disclosure: The 8-K filing is designated under “Item 8.01 — Other Events,” but there is no specific event or business update disclosed in the filing.
• No Soliciting, Written, or Pre-commencement Communications:
  • The company indicated “false” for communications under SEC Rules 425, 14a-12, 14d-2(b), and 13e-4(c), meaning the filing is not related to merger proxy solicitations, tender offers, or similar price-sensitive events.
• Signature: The filing is signed by Steven Lo, President and Chief Executive Officer, on behalf of Vaxart, Inc., dated April 21, 2026.

What Investors Need to Know

• No Material Event Disclosed: The Form 8-K does not disclose any new business developments, financial results, M&A activity, management changes, litigation, regulatory updates, or cybersecurity incidents. This filing appears to be a routine or administrative update.
• No Price-Sensitive Information: There are no announcements or disclosures in this 8-K that would typically be expected to move the share price, such as new product launches, strategic partnerships, or material events.
• Stock Still Trades on OTCQX: Vaxart’s common stock continues to trade exclusively on the OTCQX® Best Market under the symbol “VXRT.” There is no indication of uplisting, delisting, or change in trading venue.
• Legal and Administrative Clarity: All company information — including name, address, and core regulatory filings — is confirmed and up to date. There is no evidence of amendments or corrections to previous filings.

Conclusion

Bottom Line for Shareholders: The current Form 8-K filing by Vaxart, Inc. does not contain any new, material, or price-sensitive information. It serves to confirm the company’s legal and administrative standing as of April 20, 2026, with no events or developments announced that should impact the share price. Investors should be aware that this is a standard compliance filing and does not indicate any changes in business strategy, management, financial outlook, or regulatory status.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence or consult with a licensed financial advisor before making any investment decisions. No warranty is made regarding the accuracy or completeness of the information contained herein.

View Vaxart, Inc. Historical chart here